Related Experiment Video
Updated: Apr 15, 2026
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
Published on: January 10, 2025
Effects of fulvestrant on biological activity and Wnt expression in rat GH3 cells
Jiwei Bai1, Yan Wang2, Chuzhong Li1
1Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China.
Abstract:
The present study investigated the influence of anti-estrogen treatment (fulvestrant) on pituitary adenoma cell line GH3 biological activity, the estrogen receptor α pathway, the WnT pathway, and mechanisms of decreased Wnt inhibitory factor-1 expression in GH3 cells. Results showed that fulvestrant suppressed GH3 cell proliferation and reduced hormone secretion in a dose-dependent manner. Estrogen receptor α and Wnt4 expression decreased, but Wnt inhibitory factor-1 expression increased in a dose-dependent manner following fulvestrant treatment, and β-catenin expression remained unchanged. Inhibitors of DNA methylation and histone modification upregulated Wnt inhibitory factor-1 expression. Results suggested that fulvestrant suppressed biological activity of GH3 cells via the estrogen receptor α and Wnt pathways. These results suggested that decreased Wnt inhibitory factor-1 expression in GH3 cells played a role in epigenetic mechanisms. Anti-estrogen therapies could provide novel treatments for growth hormone adenomas.
Insights
Anti-estrogen therapy with fulvestrant reduces pituitary adenoma cell growth and hormone secretion. This treatment impacts estrogen receptor alpha and Wnt pathways, suggesting new therapeutic strategies for growth hormone adenomas.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Pituitary adenomas, particularly growth hormone-secreting adenomas, represent a significant clinical challenge.
- Understanding the molecular pathways regulating pituitary adenoma growth is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the effects of the anti-estrogen fulvestrant on the biological activity of the GH3 pituitary adenoma cell line.
- To elucidate the impact of fulvestrant on the estrogen receptor alpha (ERα) and Wnt signaling pathways.
- To explore the mechanisms underlying altered Wnt inhibitory factor-1 (WIF-1) expression in response to fulvestrant.
Main Methods:
- GH3 cells were treated with varying doses of fulvestrant.
- Cell proliferation and hormone secretion were measured.
- Expression levels of ERα, Wnt4, Wnt inhibitory factor-1 (WIF-1), and β-catenin were analyzed.
- Epigenetic modifiers (DNA methylation and histone modification inhibitors) were used to study WIF-1 regulation.
Main Results:
- Fulvestrant significantly suppressed GH3 cell proliferation and hormone secretion in a dose-dependent manner.
- Treatment led to decreased expression of ERα and Wnt4, while WIF-1 expression increased dose-dependently.
- β-catenin expression remained unaffected by fulvestrant.
- Epigenetic modifiers upregulated WIF-1 expression, suggesting a role for epigenetic mechanisms in WIF-1 regulation.
Conclusions:
- Fulvestrant exerts its suppressive effects on GH3 cell biological activity through the ERα and Wnt signaling pathways.
- Decreased WIF-1 expression in GH3 cells is linked to epigenetic modifications.
- Anti-estrogen therapies, like fulvestrant, show potential as novel therapeutic strategies for growth hormone adenomas.
